Deal of the Week: Prelude Fertility/Vivere Health
Two fertility clinics are banking on growth through acquisitions. At least, their investors are. Miami, Florida-based Prelude Fertility last week announced its acquisition of Vivere Health, LLC, a portfolio company of LLR Partners. Franklin, Tennessee-based Vivere operates fertility practices and labs in partnership with fertility specialists in nine U.S. markets. Since its founding in 2010, it has partnered with fertility specialists to promote or establish their practices while removing the burdens of day-to-day management. It also has egg banking services and a mail-order pharmacy. Prelude Fertility is a reproductive science and technology company. It operates fertility treatment... Read More »
DaVita Dumps Its Doc Group for $4.9 Billion
Kidney care specialist DaVita (NYSE: DVA) made good on its statement that it was exploring strategic alternatives for its DaVita Medical Group (DMG). It found a buyer in UnitedHealth Group’s (NYSE: UNH) Optum, which agreed to pay $4.9 billion for DMG, the highest publicly announced price it has paid for a physician group. In January, Optum announced its take-out of Surgical Care Affiliates, Inc. (NASDAQ: SCAI) for $3.2 billion. The company partners with health plans, medical groups and health systems to develop and optimize surgical centers. At the time of the announcement, it operated 205 surgical facilities, including ambulatory surgery centers and surgical hospitals, in partnership with... Read More »
CVS, Aetna Lead a Potential Big-Deal Parade
The fourth quarter, and the month of December in particular, are usually busy times for mergers and acquisitions, and often when big deals are announced. With one month to go in Q4:17, the pace may be picking up. Deal volume through December 1 stood at 231 transactions (-39% to last year’s 379), and $19.6 billion (-49% vs. $38.6 billion in Q4:16). But late on December 3, CVS Health (NYSE: CVS) and managed care giant Aetna (NYSE: AET) announced their $69 billion merger. More mega-deals are in the offing. Possibly. The CVS/Aetna deal was first reported in October by The Wall Street Journal, with talk of $200 to $205 per share for Aetna. The final price is $207 per share in cash and... Read More »
Dermatology Practice Deals Up 46% in 2017
Acquisitions of dermatology practices are surging in 2017. Through mid-November, we’ve counted 37 transactions for these physician practices, up nearly 46% compared with all of 2016 (26 announced transactions), according to our Deal Search Online database. As we’ve noted before, private equity play a significant role in the increased deal count. Epiphany Dermatology, a portfolio company of CI Capital Partners, has been the busiest acquirer this year, with eight transactions concentrated in Arizona, New Mexico, Oklahoma and Texas. All had three or fewer physicians, and none of the deals disclosed prices. Two privately held companies have announced five transactions apiece in... Read More »
Cardinal Health Sheds its China Operations
Cardinal Health Inc. (NYSE: CAH) put its Cardinal Health China business up for sale in July of this year, following concerns that upcoming drug distribution reform could threaten the company’s growth. Cardinal’s China business is the eighth largest drug distributor in the country, operating 14 direct sales units and 17 distribution centers that cover 322 cities and 11,000 medical institutions. The bidding process was very competitive, according to Reuters, and names like Warburg Pincus were rumored to have competed in the final rounds, among other private equity and Chinese pharmaceutical bidders. On November 14th, Cardinal Health announced that Shanghai Pharmaceuticals Holding Co., Ltd.... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
